OTC Markets OTCPK - Delayed Quote USD

Imugene Limited (IUGNF)

0.0290

-0.0011

(-3.65%)

At close: January 10 at 3:00:00 PM EST

ASX Penny Stocks To Watch In January 2025

As 2024 closed, the Australian market experienced a downturn, with the ASX finishing on a two-day decline, highlighting profit-taking across most sectors. Despite this broader market pullback, investors continue to seek opportunities in undervalued areas such as penny stocks. Though often considered niche or outdated, these smaller or newer companies can offer significant growth potential when supported by strong financials.

Simply Wall St. 10 days ago

TPGTF

LRSRF

IUGNF
-3.65%
ASX Penny Stocks To Watch In November 2024

The Australian market has recently seen the ASX200 reach new heights, closing up 0.45% at 8,444 points, with Health Care and Financials leading the charge despite mixed performances in other sectors. In such a dynamic market landscape, identifying promising investment opportunities requires careful consideration of financial health and growth potential. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for investors seeking value beyond...

Simply Wall St. last month

AX1.AX

VNT.AX

IUGNF
-3.65%
3 Promising ASX Penny Stocks With Market Caps Over A$10M

The Australian market remained flat over the last week, but it has seen a 22% rise in the past 12 months, with earnings forecasted to grow by 12% annually. For investors willing to explore beyond established names, penny stocks—often smaller or newer companies—can offer intriguing opportunities. While the term might seem outdated, these stocks can still provide significant growth potential when supported by strong financials and solid fundamentals.

Simply Wall St. 2 months ago

RIL.AX

CTLLF

IUGNF
-3.65%
Those who invested in Imugene (ASX:IMU) five years ago are up 144%

It might be of some concern to shareholders to see the Imugene Limited ( ASX:IMU ) share price down 19% in the last...

Simply Wall St. 3 months ago

IUGNF
-3.65%
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)

10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy)1Cohort B: 4 patients were treated with azer-cel, lymphodepletion (chemotherapy)1, and interleukin 2 (IL-2) 3 complete responses - The first 2 patients treated in Cohort B achieved a complete response (CR) and 1 patient treated in Cohort A achieved a CRDurability of CRs in Cohort B; >120 days and >90 days

GlobeNewswire 4 months ago

IUGNF
-3.65%
Breakeven On The Horizon For Imugene Limited (ASX:IMU)

Imugene Limited ( ASX:IMU ) is possibly approaching a major achievement in its business, so we would like to shine some...

Simply Wall St. 5 months ago

IUGNF
-3.65%
Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 7 months ago

IUGNF
-3.65%
Those who invested in Imugene (ASX:IMU) five years ago are up 361%

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...

Simply Wall St. 8 months ago

IUGNF
-3.65%
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma)Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieved a complete response and another patient achieved stable diseaseThe fifth cohort in the intratumoural (IT) arm of the VAXINIA monotherapy trial has now been cleared with no safety signals seen to date; the c

GlobeNewswire 8 months ago

IUGNF
-3.65%
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXINIA efficacy, including a complete response (CR) and two partial responses (PRs), has warranted cohort expansions in biliary tract cancer and other tumour types.Compared to chemotherapy alone, vaccination with HER-Vaxx was associated with a 40% overall survival benefit.HER-Vaxx induced HER2-specific antibody levels correlate with tumour reduction. SYDN

GlobeNewswire 8 months ago

IUGNF
-3.65%
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

The OASIS trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by CD19-targeting therapeutics such as Amgen’s Blincyto®, Gilead’s Yescarta® and Imugene’s own allogeneic CAR T Azer-celOASIS potentially represents a paradigm shift in solid tumour treatmentCohort Review Committee (CRC) observed no safety issues in the onCARlytics monotherapy lead-in study and recommended opening of the combination arm of the studyOvarian, breast

GlobeNewswire 9 months ago

IUGNF
-3.65%
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signalsEncouraging early results from the VAXINIA (CF33) oncolytic virus trial, including one complete response in a patient with cholangiocarcinoma (bile tract cancer) and two partial responses in patients with melanoma; two out of three of the responses were achieved with monotherapy CF33; receipt of US FDA Fast Track Designation for bile duct cancerPotential near-term registrational st

GlobeNewswire 10 months ago

IUGNF
-3.65%
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer along with additional novel cell therapy programsROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commerci

GlobeNewswire 11 months ago

MXCT

IUGNF
-3.65%
Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium

SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) currently ...

ACCESSWIRE 11 months ago

IUGNF
-3.65%

Performance Overview

Return	IUGNF	S&P/ASX 200 [XJO]
YTD	+9.43%	+1.65%
1-Year	-65.88%	+11.05%
3-Year	-89.81%	+11.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Imugene Limited (IUGNF)

ASX Penny Stocks To Watch In January 2025

ASX Penny Stocks To Watch In November 2024

3 Promising ASX Penny Stocks With Market Caps Over A$10M

Those who invested in Imugene (ASX:IMU) five years ago are up 144%

Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)

Breakeven On The Horizon For Imugene Limited (ASX:IMU)

Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?

Those who invested in Imugene (ASX:IMU) five years ago are up 361%

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium

Performance Overview